Introduction {#s1}
============

Neurodegenerative disorders (NDDs) are a group of unexplained chronic progressive neurological diseases based on neuronal degeneration, including Parkinson' disease (PD), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Huntington's disease (HD) ([@B27]). The neuroinflammatory reactions in the pathogenesis of NDDs have received more and more attention, and it has become a research hotspot in related fields ([@B74]). The role of neuroinflammation in the progression of different neurological diseases varies according to its role in the severity and progression of the disease ([@B10]). Studies have confirmed that the occurrence and development of many NDDs are closely related to neuroinflammation, among which activation of microglia is considered to be the key factor contributing to the upsurge ([@B80]). Microglia are the resident macrophages of the central nervous system (CNS), accounting for about 10% of the total number of adult brain cells. Microglia play the important role of immune defense guardian and are responsible for protecting the brain from damage and invasion by pathogens. When neurons are damaged, microglia activate and undergo morphological changes, releasing a series of inflammatory cytokines to alleviate neuronal damage. However, microglia are also a "double-edged sword" ([@B47]). Chronic inflammatory stimuli persist in NDDs, and activation of microglia results in the release of inflammatory factors, resulting in further neuronal damage.

Neurodegenerative Disorders and Inflammation {#s2}
============================================

Microglia are an important component of the nervous system, including central and peripheral glial cells. Central glial cells mainly include astrocytes, oligodendrocytes microglia, and ependymal cells. Microglia are small in size and the main cells involved in the nervous system inflammatory response. They have the function of phagocytosis and clearing of cell debris and are the "macrophages" of the brain. Microglia are divided into resting and activated cells. Resting microglia are small and do not participate in the inflammatory reaction, whereas activated microglia are larger in volume, have a phagocytic function and participate in the inflammatory reaction. Under the influence of various factors, microglia secrete various cytokines, such as interferon-γ (IFN-γ), interleukin-β (IL-β), and tumor necrosis factor-α (TNF-α), which are involved in the inflammatory response ([@B14]; [@B69]), [**Figure 1**](#f1){ref-type="fig"}.
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AD has been associated with chronic neuroinflammation and microglia activation ([@B54]). Under the condition of AD pathology, dangerous-associated molecular patterns, amyloid-β peptide (Aβ), neurotrophic plaques (NPs), neurofibrillary tangles activate pattern recognition receptors (PRRs) and related complements on microglia and neuron surfaces cause a chronic inflammatory response, leading to neuronal damage ([@B68]). PRRs include Toll-like receptors, formyl peptide receptors, NOD-like receptors, receptors for advanced glycation end products, and the α7-nicotinic acetylcholine receptor ([@B37]). Activated microglia produce potential neurotoxic inflammatory factors, and the main AD-related inflammatory factors are TNF-α, IL-1, and IL-6. TNF-α is an inflammatory signaling factor that triggers a downstream cascade and regulates synaptic connections between neurons through corresponding receptors. Elevated levels of TNF-α in cerebrospinal fluid lead to synaptic dysfunction in patients with AD. Similarly, TNF-α also leads to dysfunction of endothelial cells and microvessels, amyloid production, and amyloid-induced memory impairment in patients with AD. Aβ activates the TNF-α-dependent intracellular signal transduction pathway, leading to upregulation and activation of cyclooxygenase-2 (COX-2) expression, which ultimately leads to neuronal synaptic loss and cognitive decline ([@B83]; [@B55]). IL-6 exists during the early stage of NP formation and increases significantly in patients with AD. IL-1 and IL-6 co-activate to upregulate expression of the tau protein phosphokinase cdk5/p35 complex. IL-1β activates mitogen activated protein kinase (MAPK)-p38 and induces inducible nitric oxide synthase (iNOS), leading to neuronal damage and death ([@B65]). Although microglia protect the CNS by phagocytosis of Aβ and synaptic strippers, continuously activated microglia produce a variety of inflammatory factors and neurotoxins, leading to neuronal damage, which has a negative impact on the occurrence of AD.

PD is a common neurodegenerative disease in the elderly. Pathological changes include degenerative loss of dopaminergic neurons in the substantia nigra and formation of eosinophilic inclusion bodies in neurons. Malu et al. reported numerous activated microglia and cytokines in the substantia nigra compacta of PD patients during autopsy, further suggesting that activation of microglia is related to the degeneration of dopaminergic (DA) neurons ([@B81]). [@B26] reported obvious inflammatory reactions in the pons, basal ganglia, striatum, and frontotemporal lobe of patients with PD, suggesting that microglia in specific parts of the brain of patients with PD are activated during the early stage of disease. A growing body of research has confirmed that a variety of pathological changes in patients with PD activate microglia, including the main component of Lewy bodies (α-synuclein), thrombin and immunoglobulin activated protease-activated receptor-1 and Fc receptors; ATP released by injured neurons binds to the purine receptor; matrix metalloproteinase 3 (MMP-3); neurons in the inflammatory response, CD200 surface expression is downregulated, and inhibiting CD200 can activate microglia and induce microglia to release neurotoxic inflammatory factors ([@B43]; [@B50]; [@B31]; [@B20]). Inflammatory factors are highly expressed in the substantia nigra striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD mice and in autopsy specimens of patients. IL-1β directly induces the death of DA neurons. Gayle et al. blocked IL-1β and TNF-α with neutralizing antibodies to show that nearly 50% of the death of DA neurons induced by lipopolysaccharide (LPS) were caused by these two factors. Therefore, inflammatory factors secreted by activated glial cells are involved in the degeneration of DA neurons. In addition, activated microglia accelerate the progress of PD by inducing oxidative stress and cytokine toxicity through inflammatory factors ([@B96]). The microglia reaction plays a much more destructive than beneficial role in PD. Although the microglia reaction is not necessarily the initial step causing degeneration of DA neurons in the substantia nigra parotid, the microglia reaction is likely to involve and accelerate degeneration of DA neurons. The treatment to inhibit gliosis and iNOS-induced neurodegeneration represents one of the most promising therapeutic strategies for delaying and even preventing PD progression. Therefore, studying the relationship between microglia activation and PD will help to elucidate the etiology and pathogenesis of PD.

HD is an autosomal dominant inheritance disease affecting the striatum and cerebral cortex with a complete penetration rate of 50% in the offspring of affected individuals. HD is caused by *Huntingtin* mutation on chromosome 4 short arm 4p16.3. The gene product is CAG trinucleotide repeat amplification to produce Huntingtin protein. There are 11 to 34 CAG repeats in normal people, and HD is more than 40 ([@B66]). HD is no exception, as there is increasing evidence that activated microglia can be detected in the brains of HD carriers and the post-mortem HD patients. In particular, elevated inflammatory cytokines are detected in the CNS and plasma of HD patients ([@B62]; [@B89]). Neuronal expression of mutant HTT and intrinsic mutant protein may be responsible for activating microglia. Activated microglia are present in a continuum of two functional states of polarization (M1 and M2 phenotypes) in which they extend damage to neighboring cells and then release different inflammatory factors ([@B89]). These inflammatory factors include pro-inflammatory cytokines (TNF-α and IL-1 β), chemokines (CCL2), MMP-9, IL-10, TGF-β, vascular endothelial growth factor, and insulin-like growth factor-1, which further activate the microglia activation signaling pathway in HD ([@B12]; [@B13]; [@B24]; [@B59]).

ALS is a chronic and lethal NDD involving mainly motor neurons in the cerebral cortex, brainstem, and spinal cord. Neuroinflammation is observed in superoxide dismutase 1 (SOD-1)-transgenic mice and in patients with sporadic and familial ALS. Activation of microglia occurs before the loss of motor neurons ([@B28]). David et al. demonstrated that microglia accumulate in the spinal cord and peripheral nerves during the early stage of ALS and reported that activation of microglia is earlier than the clinical manifestation of ALS, indicating that microglia activate during the early stage of ALS leading to progression of the disease ([@B30]). SOD-1 activates microglia directly. In addition, T cells activate microglia by directly contacting or releasing proinflammatory factors (IFN-γ). The chemokine monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid chemotactically aggregates a large number of microglia into motor neurons ([@B4]; [@B25]). Activated microglia lead to neuronal death through the following pathways: the TNF-α-mediated apoptotic mechanism and Fas ligand or the nitric oxide-induced apoptotic pathway ([@B72]). In addition, p38MAPK activation further increases the synthesis of inflammatory factors and promotes the inflammatory response; NF-κB activation leads to increased transcription of a series of inflammatory-related genes, including IL-2, IL-6, IL-8, IL-12p4, COX-2, iNOS, MMP-9, and MCP-1. Increased expression of the fractalkine receptor (CX3CR1) produces neurotoxic effects ([@B72]; [@B17]; [@B41]). Inflammatory and cytotoxic factors released by activated microglia can induce or enhance progressive and selective motor neuron degeneration. However, the ALS inflammatory response involving microglia is complex. Although the specific mechanisms are still unclear, the interventions designed for microglia have a very attractive prospect, which may provide an effective treatment strategy for ALS.

MiR Function {#s3}
============

MiRs are small single-stranded RNAs of about 21--23 bases. They are produced by Dicer enzyme processing of about 70--90 single-stranded RNA precursors with a hairpin structure ([@B42]). The first confirmed miRs were lin-4 and let-7 found in nematodes. Subsequently, several research groups began work on humans, fruit flies, and plants, and hundreds of miRs have been identified from a variety of species ([@B32]). MiRs are involved in a series of biological processes such as cell proliferation and apoptosis, growth and development, metabolic activation, and DNA repair *in vivo*, which are closely related to the occurrence and development of various diseases, especially tumors. MiRs regulate the target gene mRNA mainly by cutting off the target gene's RNA molecule, inhibiting target gene translation, and inhibiting combining ([@B1]). Specific expression or enrichment of miRs in mammalian brain tissues have been detected, such as miR-9, miR-124, and miR-132 ([@B45]; [@B49]). MiR-124, for example, accounts for 25--48% of total mRNA in the adult brain and is highly expressed in all brain regions except the pituitary. MiR-124 is also considered to be a neuron-specific miR because it is mainly expressed in neuronal cells ([@B45]; [@B56]). MiR-124 is temporarily upregulated during neurodevelopment and adult neurogenesis ([@B76]; [@B11]). This miR also plays a key role regulating synaptic plasticity and memory signaling molecules ([@B22]). MiR-124 is also highly expressed in microglia, where it takes part in the regulation of microglia quiescence ([@B63]; [@B71]).

MiR-124 in Neurodegenerative Disorders {#s4}
======================================

MiR-124 is one of the most abundant and best studied miRNAs that functions within the nervous and immune systems ([@B78]). MiR-124 has well-established functions during neuronal development and neurodegeneration. The level of miR-124 remains high in post-mitotic neurons, suggesting that it takes part in maintenance of the differentiated state of neurons ([@B63]; [@B78]). MiR-124 also contributes to pathological conditions, while influencing microglia to adopt a surveillance state or anti-inflammatory phenotype ([@B15]; [@B3]) ([**Table 1**](#T1){ref-type="table"}). Previous studies have claimed that CNS inflammation is more prominent during the early stage of AD and microglia become less responsive to stimulation with age ([@B88]; [@B57]; [@B8]) provided the inflammation-miRNA aging characteristics of primary cultured microglia and confirmed the low expression of miR-124 in age-related neurodegenerative diseases at the cellular level through *in vitro* microglial studies at different time points. The mechanism of miR-124 involvement in AD is mainly to interfere with clearance of the amyloid precursor protein (APP). [@B21] used PC 12 cellular AD models and suggested that miR-124 dysregulation is related to AD pathology by targeting BACE1 (𝛽-site APP cleaving enzyme 1), which is a key cleaver of the APP that plays a pivotal role in 𝛽-amyloid production. Those researchers demonstrated that there was a negative regulatory relationship between miR-124 and BACE1 expression, and that miR-124 could be a promising therapeutic target in patients with AD. In brain samples of patients with AD and mouse model, [@B77] found that the expression of miR-124 was downregulated and concluded that miR-124 participates in post-transcriptional regulation of APP expression. As abnormal neuronal splicing of APP affects the production of 𝛽-amyloid peptide, their results contribute to understanding the significance of miRNAs in the pathogenesis of AD. Synaptic pathological changes usually occur during the early period of AD. Other mechanisms by which miR-124 is involved in the pathogenesis of AD have also been reported. [@B87] revealed in *in vitro* cell studies of AD patients and Tg2576 mice (a recognized AD mouse model) that tyrosine-protein phosphatase non-receptor type 1 (PTPN1) is a direct target of miR-124, and that dysregulation of miR-124 leads to dysfunctional synaptic transmission and plasticity. Affecting the miR-124/PTPN1 pathway could restore synaptic failure and memory deficits. [@B85] revealed that miR-124 is one of the most significantly dysregulated miRs in temporal cortex samples from patients with AD and predicted that dysregulation of miR-124 expression in the human brain may contribute to the pathogenic changes of AD ([@B85]). Aberrant activation of cyclin-dependent kinase-5 (CDK5) is mediated by calpain (CAPN)-induced cleavage of p35 into p25. [@B98] confirmed that miR-124 is a CAPN1-targeting miRNA, which functionally inhibits CAPN1 protein translation of HCN-2 cells. Transfection with miR-124-3p *in vitro* reduces levels of the CAPN1 protein, thereby attenuating CDK5-mediated hyperphosphorylation of APP and the tau protein. MiR-124 has been suggested to be associated with microvascular dysfunction and subsequent cognitive impairment. Downregulated expression of miR-124 results in Aβ deposition, a decline in microvascular density, and reduced angiogenesis ([@B48]). Regulating miR-124 expression may prevent the onset and progression of AD through various pathways, and provide new ideas for treating AD.

###### 

Overview of the miRNA-124 expression in the models of neurodegenerative disorders.

  Neurodegenerative disorders     Model                          MiRNA-124 expression   Molecules regulation   Possible biological function/pathological process           References
  ------------------------------- ------------------------------ ---------------------- ---------------------- ----------------------------------------------------------- ------------
  Alzheimer's disease             PC 12 cell lines and SD rat    Downregulated          BACE1                  Cleavage of amyloid precursor protein                       [@B21]
                                  Human and Neuro2a cells        Downregulated          PTBP1                  Amyloid precursor protein alternative splicing in neurons   [@B77]
                                  Tg2576 mice                    Upregulated            PTPN1                  Synaptic transmission and plasticity                        [@B86]
                                  HCN-2                          Downregulated          CAPN1                  Post-transcriptional control                                [@B97]
  Parkinson' disease              Mouse brain tissue, BV2 cell   Downregulated          MEKK3 and p-p65        MEKK3/NF-κB signaling pathways                              [@B90]
                                  Mouse brain tissue, SH-SY5Y    Downregulated          p62 and p38            Autophagy, microglial activation                            [@B91]
                                  PC12 cells and SH-SY5Y cells   Downregulated          ANXA5                  ANXA5/ERK pathway                                           [@B19]
                                  Mice model                     Downregulated          CDK5                   Calpain 1/cdk5 pathway                                      [@B40]
  Huntington's disease            Bioinformatic analysis         Downregulated          REST                   Post-transcriptional control                                [@B38]
  Amyotrophic lateral sclerosis   NSC-34 cells                   Upregulated            NF-kB activation       NF-kB activation and inflammatory factors release           [@B61]
                                  SOD1-G93A mice                 Upregulated            STAT3                  Transcriptional control                                     [@B53]

A variety of pathogenic factors are involved in the onset and progression of PD, including inflammation, particularly the microglia-mediated chronic inflammatory reaction in the brain, and miR-124 is also involved. Gong et al. reported that miR-124 was downregulated in MPTP-induced neurons and that suppressing miR-124 significantly increased cell apoptosis and autophagy-associated protein expression of DA neurons in patients with PD ([@B29]). It has been suggested that miR-124 is significantly downregulated in the MPTP-induced PD mouse model and that it inhibits neuroinflammation during the development of PD ([@B64]; [@B90]). [@B91] reported that miR-124 inhibits inflammation during the development of PD by targeting p38, p62, and autophagy, suggesting that miR-124 may be a promising treatment target for regulating the inflammatory response in patients with PD. [@B19] evaluated the mechanism and effects of miR-124 on SH-SY5Y cells and 6-hydroxydopamine (6-OHDA)-induced neurotoxicity in PC12 and reported that the miR-124-3p level was downregulated. They also revealed that annexinA5 (ANXA5) is a direct target gene of miR-124-3p, which may attenuate 6-OHDA-induced neuron injury by regulating the ANXA5/ERK pathway. MiR-124 is also involved in increasing CDK5 expression mediated by calpain 1/p25 in the MPTP-mouse model of PD. Supplementing with miR-124 *in vitro* increases cell viability and attenuates protein expression of the calpain 1/cdk5 pathway ([@B40]). [@B90] also suggested that overexpression of miR-124 in microglia could attenuate the MEKK3/NF-κB inflammatory pathway and limit the pathogenesis of PD. Previous studies have indicated that the mechanism of miR-124 in the pathogenesis of PD is relatively clear. That is to say, downregulated miR-124 promotes the pathogenesis of PD through a variety of mechanisms, and over-expression of miR-124 may play a therapeutic role in PD by preventing the inflammatory response.

There are a few studies on the relationship between miR-124 and HD. It was reported that miR-124 was downregulated in the cortex and hippocampus of HD transgenic mice ([@B39]; [@B46]). The role of RE1-silencing transcription factor (REST) in the pathogenesis of HD has been fully studied. However, miR-124 is encoded by multiple genes each targeted by REST ([@B38]).

MiR-124 is related to different phenotypes and functions of microglia, which may be a different cause of neuroinflammation in patients with ALS ([@B5]; [@B16]). Significantly upregulated miR-124 was revealed by [@B61] in NSC-34 cells (a MN-like cell line) expressing SOD1G93A. Elevated miR-124 levels are thought to have a calming effect on microglia, as miR-124 is expressed by stressed neurons associated with neurodegeneration ([@B63]). In addition, the elevated levels seem to be negatively correlated with the STAT3 transcription factor, a key factor for neural differentiation and cell survival ([@B53]). In a study of neural stem cells from ALS transgenic mice, [@B97] showed that miR-124 was downregulated in the brainstem and spinal cord, and that miR-124 may participate in astrocyte differentiation of ALS transgenic mice by targeting Sox2 and Sox9. Many studies have reported that the expression level of miR-124 is inconsistent in ALS models, which may be related to the samples selected by different studies, and more studies in the future may draw more clear conclusions. However, it is certain that miR-124 is involved in ALS through the inflammatory reaction. It will be possible to treat ALS with miR-124 as the target after further study on the pathological mechanism of ALS.

MiR-124-Based Therapeutic Strategies and MiR Delivery {#s5}
=====================================================

Although we are far from understanding the complete NDD picture, we now know that there is a clear correlation between the expression of miRNAs and neurodegeneration ([@B67]). Therapeutic strategies based on miRNAs can be direct, such as regulating target protein expression by increasing or decreasing specific levels of miRNAs, or indirect, by activating or enhancing endogenous repair mechanisms in the brain by introducing miRNAs. However, as an important potential target of NDD treatment, miRNAs still have the following shortcomings: (1) they are highly unstable and easily degraded by nucleases in the plasma; (2) because of their negative charge, miRNAs are difficult to pass through the cell membrane formed by a lipid bimolecular layer and cannot be released in the cell, resulting in low bioavailability; (3) systemic administration requires miRNAs to be targeted. Therefore, selecting a safe and efficient delivery vector is the key to the success of miRNA molecular NDD gene therapy ([@B9]; [@B6]; [@B79]; [@B95]).

Viral and non-viral vectors have been developed to improve the delivery efficiency of miRNAs. The delivery system based on a virus as the carrier is highly efficient and can deliver miRNAs to target cells effectively. For example, [@B98] administered an intracranial injection of adeno-associated virus (AAV) expressing microRNA-124-3p into APP/PS1-AD mice, showing that A𝛽 deposition was significantly reduced and AD-mouse behavior and cognitive function were significantly improved. A similar approach has been used to treat PD. [@B91] reported that exogenous delivery of miR-124 suppresses the expression of p38 and p62 and attenuates microglia activation in the substantia nigra pars compacta of MPTP-treated mice. However, the disadvantages of viral vectors (such as the immunogenicity/inflammatory response and low loading capacity) limit their application in gene delivery and make it difficult to achieve large-scale manufacturing and quality control ([@B36]; [@B51]; [@B60]). Compared with viral vectors, non-viral vector delivery systems (liposomes, polymer-based systems, and inorganic nanoparticles) are diverse and relatively safe and can effectively avoid the problems faced by viral vectors through reasonable design and appropriate modification. Therefore, non-viral vector delivery systems are widely used in clinical research ([@B92]; [@B44]). Liposomes have advantages of simple preparation, safety, and non-toxicity. Cationic liposomes or neutral liposomes have been widely studied as miRNA delivery carriers ([@B33]). Nanoparticles used for *in vivo* delivery of liposomes include cationic liposomes, neutral liposomes, and polyethylene glycol-modified liposomes. Liposome nanoparticles stabilize nucleic acids, resist enzyme degradation, promote cell uptake, and prolong the cycle half-life of miRNA ([@B35]; [@B34]; [@B2]). Negative hydrophilic miRNA interacts with the positive liposome to form a complex system through a positive and negative charge interaction, and interact with the negative cell membrane to deliver miRNA. The efficiency of the combined miRNA uptake by the cell is also improved ([@B58]; [@B82]). [@B73] developed a novel liposome-based method for delivering anti-miR-124 efficiently into live planarians to demonstrate the roles of the miR-124 family of miRs in regulating the regeneration of a functional brain. Poly lactic-co-glycolic acid (PLGA) is a Food and Drug Administration approved biocompatible polymer, which can be hydrolyzed into nontoxic lactic acid and glycolic acid monomers and metabolized by the human body without any side effects ([@B18]). PLGA polymer nanoparticles capture bioactive molecules, escape from cytolysin to the cytoplasm, induce the sustained release of transported substances in cells, and prolong efficacy. Furthermore, introducing cationic polyethyleneimine with a positive charge into the PLGA system solves the problems of low molecular weight and low over efficiency of PLGA. At present, the PLGA carrier has been widely used to deliver various therapeutic genes ([@B18]; [@B7]; [@B52]). PLGA nanoparticles have been used to efficiently deliver nicotine to the brain to achieve neuroprotective effects in PD caused by reactive oxygen species ([@B23]). Yu et al. successfully delivered ketoprofen and miR-124 co-loaded PLGA microspheres to adjuvant-induced arthritic rats and demonstrated therapeutic efficiency ([@B94]). Gold nanoparticles (AuNPs) are of great interest as non-viral gene delivery vectors due to their ease of control in size and shape, and their biocompatibility and low cytotoxicity ([@B84]; [@B93]). AuNPs maintain high stability in salt solution and specifically bind to complementary nucleic acids. In addition, magnetic nanoparticles can be used to deliver genetic material to a target site by means of an external magnetic field, thereby overcoming the disadvantage of poor transfection efficiency of the viral vector. This method reduces side effects, increases selectivity, and reduces the cost and dosage of non-viral vectors. Magnetic nanoparticles are primarily used to effectively treat cancer ([@B86]; [@B75]). [@B70] successfully constructed miRNA-124-loaded polymeric nanoparticles and injected them into a 6-OHDA-challenged mouse model of PD ventricles. The results showed that miRNA-124 NPs enhanced the migration of new neurons into the 6-OHDA lesioned striatum, culminating in improved motor function. Moreover, an exosome-based delivery method has also been successfully applied in HD research. Exo-124 (exosomes exhibit a high level of miR-124 expression) was injected into the striatum of R6/2 transgenic HD mice, and [@B46] revealed that expression of the REST target gene decreased, which participates in multiple links in the pathogenesis of HD. While no miRNA therapeutics have entered clinical trials to treat NDDs, further advances in delivering miRNA therapeutics to the desired site of action may contribute to clinical development.

Conclusions {#s6}
===========

Many processes are involved in the pathogenesis of NDDs, including transcriptional dysregulation, mitochondrial dysfunction, and synaptic dysfunction. Activation of microglia and inflammation are important pathogenic processes in NDDs. MiR-124 is closely related to the pathogenesis of NDDs and is downregulated in response to pro-inflammatory stimuli. Over-expressing miR-124 may be a viable strategy to reduce the inflammatory response associated with NDDs. However, more studies are required to investigate the specific effects of miR-124 in NDDs. Improved miR delivery methods in clinical trials may lead to the development of microglia-specific miR therapies for NDDs.
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